JP2018519802A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519802A5
JP2018519802A5 JP2017560132A JP2017560132A JP2018519802A5 JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5 JP 2017560132 A JP2017560132 A JP 2017560132A JP 2017560132 A JP2017560132 A JP 2017560132A JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5
Authority
JP
Japan
Prior art keywords
mutein
nucleotide sequence
nucleic acid
encoded
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560132A
Other languages
English (en)
Japanese (ja)
Other versions
JP6942060B2 (ja
JP2018519802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/061058 external-priority patent/WO2016184875A1/en
Publication of JP2018519802A publication Critical patent/JP2018519802A/ja
Publication of JP2018519802A5 publication Critical patent/JP2018519802A5/ja
Priority to JP2021127923A priority Critical patent/JP7217783B2/ja
Application granted granted Critical
Publication of JP6942060B2 publication Critical patent/JP6942060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560132A 2015-05-18 2016-05-18 グリピカン−３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン Expired - Fee Related JP6942060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021127923A JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167922 2015-05-18
EP15167922.2 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021127923A Division JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン

Publications (3)

Publication Number Publication Date
JP2018519802A JP2018519802A (ja) 2018-07-26
JP2018519802A5 true JP2018519802A5 (https=) 2019-06-20
JP6942060B2 JP6942060B2 (ja) 2021-09-29

Family

ID=53180583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560132A Expired - Fee Related JP6942060B2 (ja) 2015-05-18 2016-05-18 グリピカン−３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン
JP2021127923A Active JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021127923A Active JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン

Country Status (13)

Country Link
US (2) US10273275B2 (https=)
EP (1) EP3298029A1 (https=)
JP (2) JP6942060B2 (https=)
KR (1) KR20180008649A (https=)
CN (2) CN114456252A (https=)
AU (1) AU2016262838B2 (https=)
BR (1) BR112017020961A2 (https=)
CA (1) CA2982034A1 (https=)
MX (1) MX2017014730A (https=)
RU (1) RU2756318C2 (https=)
SG (1) SG11201707872WA (https=)
WO (1) WO2016184875A1 (https=)
ZA (1) ZA201706605B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
SG11201609274SA (en) 2014-05-22 2016-12-29 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
MX2021010039A (es) * 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007107563A2 (en) * 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
KR101570252B1 (ko) 2007-07-17 2015-11-19 메다렉스, 엘.엘.시. 글리피칸-3에 대한 단클론 항체
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
BR112012013662B1 (pt) * 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2014076321A1 (en) * 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)

Similar Documents

Publication Publication Date Title
JP2018519802A5 (https=)
JP2018532372A5 (https=)
JP2018515084A5 (https=)
JP2014502149A5 (https=)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2017518748A5 (https=)
JP2019506140A5 (https=)
JP2020505948A5 (https=)
US10233238B2 (en) TNF alpha antibody or fragment thereof and methods of use
JP2013512683A5 (https=)
RU2015137158A (ru) МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
JP2018526989A5 (https=)
RU2019122482A (ru) Мутеины липокалина с аффинностью связывания в отношении lag-3
RU2017128105A (ru) Новые белки, специфические в отношении ангиогенеза
JP2017527272A5 (https=)
JP2018509887A5 (https=)
CN114539411B (zh) 一种ror1抗体或其抗原结合片段
JP2018519803A5 (https=)
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
JP2002542157A5 (https=)
JP2016519051A5 (https=)
KR20150058454A (ko) 알부민 결합 폴리펩타이드
CN110167959A (zh) 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白
KR20160138133A (ko) 안정화된 피브로넥틴 기반 스캐폴드 분자
ZA200601900B (en) Therapeutic uses of chemokine variants